Shares of Bristol Myers Squibb Co. BMY rallied 1.86% to $50.94 Tuesday, on what proved to be an all-around favorable trading ...

With an FDA action date of Sept. 26, Bristol Myers Squibb’s KarXT could soon be the first new type of schizophrenia drug in ...

As the FDA prepares to render a verdict on BMS’ closely watched schizophrenia drug, BioSpace takes a closer look at the ...

The hits just keep on coming for Bristol Myers Squibb staffers amid the company's cost-savings program.  | Bristol Myers ...

BMO Capital analyst Evan Seigerman maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) today and set a price target ...

Dudley’s appointment follows several other senior leadership hires at BMS in recent months. These include Brad Melvin as BMS ...

In the assessment of 12-month price targets, analysts unveil insights for Bristol-Myers Squibb, presenting an average target ...

Bristol Myers Squibb (BMY) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

We recently compiled a list of the 10 Best Beaten Down Dividend Stocks to Invest in Now. In this article, we are going to ...

Given the vast amount of money and research capacities at their disposal, institutional ownership tends to carry a lot of ...

BMS Group, the independent specialist insurance and reinsurance broker, has appointed Richard Dudley as group chief broking ...